Evanthia Galanis, M.D.
Long-Term Research Aim:
To successfully treat solid tumors employing gene transfer and virotherapy approaches.
Mid-Term Research Aims:
I am principal investigator in several clinical trials through the Division of Medical Oncology, examining the therapeutic potential of: 1) a measles virus derivative encoding the human carcinoembryonic antigen (MV-CEA) in patients with recurrent glioblastoma multiforme; 2) a measles virus derivative encoding the sodium iodine symporter gene (MV-NIS) in patients with recurrent ovarian cancer; 3) a phase II trial of Reovirus in patients with metastatic melanoma; 4) a phase II trial of vaccinia virus in patients with hepatocellular carcinoma; 5) several trials of small molecule cell cycle inhibitors such as histone deacetylase inhibitors, proteasome inhibitors, sarc-kinase inhibitors and antiangiogenesis approaches in glioma patients, conducted through the North Central Cancer Treatment Group (NCCTG).
""Development and application of quantitative immunoenzymatic assays (ELISAS) and immunoblotting techniques in the study of specificity and title of M1- antimitochondrial antibodies (M2-AMA).
© 2013 Mayo Foundation for Medical Education and Research. All rights reserved.